PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the third quarter and the nine months ended September 30, 2015.
The Company is developing four potentially class-leading investigational compounds through clinical trials:
1. A PCSK9 inhibitor (ALN-PCSsc) which is emerging as a potential best-in-class treatment for LDL-C reduction and which is entering phase 2 trials
Help employers find you! Check out all the jobs and post your resume.
